Demand for coxsackievirus infections treatment will increase through 2036, with anti-inflammatory drugs at 34.2% of the drug type segment in 2026. Oral administration leads with a 56.7% share. The market was valued at USD 6.44 billion in 2025, reaching USD 6.9 billion by 2026-end and USD 14.9 billion by 2036.